Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.
Institute of Molecular Cell and Systems Biology, University of Glasgow, UK.
Pharmacol Ther. 2018 Dec;192:20-41. doi: 10.1016/j.pharmthera.2018.06.012. Epub 2018 Jun 25.
The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only in terms of hospitalization and reduction in symptoms severity, but also in terms of safety, socialization and better rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D receptor antagonists and they act beyond D antagonism, involving other receptor targets which regulate dopamine and other neurotransmitters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D receptors. This review revisits previous and current findings within the class of AAPs and highlights the differences in terms of receptor properties and clinical activities among them. Furthermore, we propose a continuum spectrum of "atypia" that begins with risperidone (the least atypical) to clozapine (the most atypical), while all the other AAPs fall within the extremes of this spectrum. Clozapine is still considered the gold standard in refractory schizophrenia and in psychoses present in Parkinson's disease, though it has been associated with adverse effects like agranulocytosis (0.7%) and weight gain, pushing the scientific community to find new drugs as effective as clozapine, but devoid of its side effects. To achieve this, it is therefore imperative to characterize and compare in depth the very complex molecular profile of AAPs. We also introduce relatively new concepts like biased agonism, receptor dimerization and neurogenesis to identify better the old and new hallmarks of "atypia". Finally, a detailed confrontation of clinical differences among the AAPs is presented, especially in relation to their molecular targets, and new means like therapeutic drug monitoring are also proposed to improve the effectiveness of AAPs in clinical practice.
自发现其原型药物氯氮平以来,非典型抗精神病药 (AAP) 的引入是治疗精神病患者的药理学革命性步骤,因为这些药物不仅在住院和减轻症状严重程度方面,而且在安全性、社交和更好地在社会中康复方面都取得了显著的恢复。关于作用机制,AAP 是弱 D 受体拮抗剂,它们的作用超出了 D 拮抗作用,涉及调节多巴胺和其他神经递质的其他受体靶标。因此,AAP 显著减少了诸如帕金森病、高催乳素血症、冷漠和快感缺失等有害副作用,这些副作用都与 D 受体的强烈阻断有关。本综述回顾了 AAP 类药物的先前和当前发现,并强调了它们之间在受体特性和临床活性方面的差异。此外,我们提出了一个从利培酮(最不典型)到氯氮平(最典型)的“非典型性”连续谱,而所有其他 AAP 都属于该谱的极端。氯氮平仍然被认为是难治性精神分裂症和帕金森病中出现的精神病的金标准,尽管它与粒细胞缺乏症(0.7%)和体重增加等不良反应有关,这促使科学界寻找与氯氮平一样有效但没有副作用的新药。为此,因此必须深入表征和比较 AAP 的非常复杂的分子特征。我们还引入了相对较新的概念,如偏向激动剂、受体二聚化和神经发生,以更好地识别“非典型性”的新旧特征。最后,特别介绍了 AAP 之间的临床差异的详细对比,尤其是与它们的分子靶标有关的差异,并提出了新的方法,如治疗药物监测,以提高 AAP 在临床实践中的有效性。